Registry Shows 93% Stroke Clot Removal Success
Terumo Neuro's RESTORE registry data, published in the Journal of NeuroInterventional Surgery, reports outcomes from 688 stroke patients treated with its device.
Updated on Nov. 17, 2026 in Stroke

Terumo Neuro published results from its prospective observational RESTORE registry in the Journal of NeuroInterventional Surgery. The analysis included 688 patients, with final successful reperfusion reported at 93.0% and symptomatic intracranial hemorrhage within 24 hours at 0.6%.
Why it matters
Mechanical thrombectomy is a key treatment for large-vessel ischemic stroke, and real-world registry data help show how device performance holds up outside controlled trials. The findings add to the evidence clinicians weigh when choosing reperfusion approaches for patients.
The registry enrolled 710 patients between June 2022 and December 2024, and functional independence (mRS ≤2) at 90 days was 52.9% among patients in the 90-day analysis. Device-related serious adverse events were 3.5%, and successful navigation was 97.4%, though the study does not compare these figures against a control group.
The players
Terumo Neuro
Terumo Neuro is the neurovascular division of Japan-based medical device maker Terumo Corporation, headquartered in Aliso Viejo, California, that develops devices for treating stroke and other neurovascular conditions.
The details
Researchers in the RESTORE registry tracked patients treated with Terumo Neuro's devices, with angiographic outcomes independently assessed by a Core Laboratory and safety outcomes adjudicated by a Clinical Events Committee. The median time from puncture to clot contact was 13 minutes.
Timeline
June 2022: RESTORE registry enrollment began.
December 2024: RESTORE registry enrollment ended.
November 17, 2026: Results were published in the Journal of NeuroInterventional Surgery.
Health Landscape
Real-world thrombectomy registries like RESTORE complement randomized trials by showing how reperfusion and safety outcomes look in routine practice, where treating physicians choose devices and patients are less tightly selected. Results from such registries are increasingly used to inform how stroke centers evaluate endovascular devices alongside trial evidence.
For patients who have a large-vessel stroke, the registry suggests that thrombectomy can restore blood flow in most cases, though these results come from a study without a comparison group. Patients and families should discuss device options and expected outcomes directly with their treating stroke team.
The takeaway
Registry data suggest that most patients treated with this device achieved successful clot removal with low rates of serious bleeding, though the lack of a comparison group limits how far these figures can be generalized. Readers should look to randomized trial evidence and clinician guidance when weighing treatment options.
Further reading
For background on the condition these devices treat, see the Stroke section.
More information
Read the full RESTORE study in Journal of NeuroInterventional Surgery.
Source note: This article includes information reported by The Manila times.



